

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:20:41 ON 31 JAN 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:20:50 ON 31 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1

DICTIONARY FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10564506a.str



chain nodes :
 7 8 9 10 11 12 13 14 19
 ring nodes :
 1 2 3 4 5 6
 chain bonds :
 1-14 4-7 7-8 7-13 8-9 8-11 8-12 9-10 14-19
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-13 9-10
 exact bonds :
 1-14 7-8 8-9 8-11 8-12 14-19
 isolated ring systems :
 containing 1 :

G1:H,Ak


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:21:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 92 TO ITERATE

100.0% PROCESSED 92 ITERATIONS

16 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1265 TO 2415

PROJECTED ANSWERS: 80 TO 560

L2 16 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:21:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1969 TO ITERATE

100.0% PROCESSED 1969 ITERATIONS

260 ANSWERS

SEARCH TIME: 00.00.01

L3 260 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
178.36	178.57

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:21:22 ON 31 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 30 Jan 2008 (20080130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 13 full
L4 9 L3

=> d ibib abs hitstr tot

ACCESSION NUMBER: 2006:11297 CAPLUS
 DOCUMENT NUMBER: 144:108213
 TITLE: Preparation of piperidine and 8-azabicyclo[3.2.1]octane derivatives as modulators of chemokine receptor CCR5
 INVENTOR(S): Faull, Alan; Tucker, Howard
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006001752	A1	20060105	WO 2005-SE953	20050620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005257708	A1	20060105	AU 2005-257708	20050620
CA 2570893	A1	20060105	CA 2005-2570893	20050620
EP 1761491	A1	20070314	EP 2005-754141	20050620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 101006057	A	20070725	CN 2005-80028432	20050620
US 2008021038	A1	20080124	US 2006-628808	20061207
IN 2007DN00246	A	20070803	IN 2007-DN246	20070109
PRIORITY APPLN. INFO.: SE 2004-1656 A 20040624				
WO 2005-SE953 W 20050620				

OTHER SOURCE(S): MARPAT 144:108213
 GI




AB Title compds. represented by the formula I [wherein A = absent or CH₂CH₂; R₁ = alkyl, amide, (hetero)aryl, etc.; R₂ = (un)substituted Ph or heteroaryl; R₃ = H or alkyl; R₄ = halo, hydroxy, cyano, etc.; R₅ = aryl, alkoxyaryl, alkylaryl, etc.; and pharmaceutically acceptable salts thereof] were prepared as chemokine receptor (CCR5) modulators. For example, II was provided in a multi-step synthesis starting from 4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidine. I were tested activity as CCR5 modulators for inhibiting the binding of RANTES and MIP-1α, certain compds. have an IC₅₀ of less than 50 μM. Thus, I and their pharmaceutical compns. are useful for the treatment of CCR5-mediated diseases.

IT 872849-72-4P 872849-73-5P 872849-74-6P
 872849-75-7P 872849-76-8P 872849-77-9P
 872849-78-0P 872849-79-1P 872849-80-4P
 872849-81-5P 872849-82-6P 872849-83-7P
 872849-84-8P 872849-85-9P 872849-86-0P
 872849-87-1P 872849-88-2P 872849-89-3P
 872849-90-6P 872849-91-7P 872849-92-8P
 872849-93-9P 872849-94-0P 872849-95-1P
 872849-96-2P 872849-97-3P 872849-98-4P
 872849-99-5P 872850-00-5P 872850-01-6P
 872850-09-4P 872850-10-7P 872850-11-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine and 8-azabicyclo[3.2.1]octane derivs. as CCR5 modulators)


RN 872849-72-4 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-73-5 CAPLUS
 CN 4-Piperidinol, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-74-6 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-methoxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-75-7 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-fluoro-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-76-8 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-ethyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 872849-77-9 CAPLUS
CN 4-Piperidinecarbonitrile, 1-((3R)-3-(3,5-difluorophenyl)-3-[[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-78-0 CAPLUS
CN Piperidine, 4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-[[3R]-3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 872849-81-5 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)propyl]-4-fluoro-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-82-6 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-2H-pyran-4-yl)propyl]-4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-83-7 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-79-1 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-2H-pyran-4-yl)propyl]-4-fluoro-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-80-4 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-fluoro-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-84-8 CAPLUS
CN 4-Piperidinol, 1-[(3R)-3-(3,5-difluorophenyl)-3-[[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-85-9 CAPLUS
CN 4-Piperidinol, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-2H-pyran-4-yl)propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-86-0 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[(2S)-tetrahydro-2-methyl-2H-pyran-4-yl]propyl]-4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-87-1 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[(2S)-tetrahydro-2-methyl-2H-pyran-4-yl]propyl]-4-fluoro-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-90-6 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-methoxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-91-7 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-methoxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-88-2 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)propyl]-4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-89-3 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-ethyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872849-92-8 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-2H-pyran-4-yl)propyl]-4-methoxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 872849-93-9 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-methoxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 872849-94-0 CAPLUS
CN 4-piperidinol, 1-[(3R)-3-{3,5-difluorophenyl}-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-[2-[(4-methoxyphenyl)sulfonyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 872849-95-1 CAPLUS
CN Piperazine,
1-[(1S)-3-[4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]e
thyl]-1-piperidinyl]-1-phenylpropyl]-4-(methylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 872849-98-4 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[(3R)-3-(3,5-difluorophenyl)-3-(tetrahydro-4-methyl-2H-pyran-4-yl)propyl]-4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 872849-99-5 CAPLUS
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-fluoro-4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-
(CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 872849-96-2 CAPLUS
CN Piperazine, 1-[(1S)-1-(3,5-difluorophenyl)-3-[4-methyl-4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]propyl]-4-(methylsulfonyl)]- (CA INDEX NAME)

Absolute stereochemistry.



RN 872849-97-3 CAPLUS
CN Piperazine, 1-[(1S)-1-(3,5-difluorophenyl)-3-[4-[2-[(4-methoxyphenyl)sulfonyl]ethyl]-4-methyl-1-piperidinyl]propyl]-4-(methylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 872850-00-5 CAPLUS

CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-{4-hydroxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 872850-01-6 CAPLUS

CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-methyl-4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 872850-09-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-methyl-4-piperidinyl]ethyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 872850-10-7 CAPLUS
CN Piperidine, 1-((3R)-3-(3,5-difluorophenyl)-3-((1-(methylsulfonyl)-4-piperidinyl)propyl)-4-methyl-4-((2-((1-(methylsulfonyl)-4-piperidinyl)sulfonyl)ethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872850-11-8 CAPLUS
CN Piperidine, 1-((3R)-3-(3,5-difluorophenyl)-3-((1-(methylsulfonyl)-4-piperidinyl)propyl)-4-methyl-4-((2-((1-(methylsulfonyl)-4-piperidinyl)sulfonyl)ethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



IT 872850-25-4P, (1S)-3-[4-Methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidin-1-yl]-1-phenylpropan-1-ol
872850-28-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of piperidine and 8-azabicyclo[3.2.1]octane deriva. as

CCR5

modulators)

RN 872850-25-4 CAPLUS
CN 1-Piperidinepropanol,
4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-
hyl]-a-phenyl-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 872850-28-7 CAPLUS
CN Piperidine, 1-((3R)-3-(3,5-difluorophenyl)-3-((1-(methylsulfonyl)-4-piperidinyl)propyl)-4-methyl-4-((2-((1-(methylsulfonyl)-4-piperidinyl)sulfonyl)ethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


ACCESSION NUMBER: 2005:99468 CAPLUS
DOCUMENT NUMBER: 142:197888
TITLE: Preparation of piperidine derivatives as chemokine receptor modulators
INVENTOR(S): Brown, Dearg; Oldfield, John; Tucker, Howard
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009959	A1	20050203	WO 2004-SE1149	20040726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1654229	A1	20060510	EP 2004-749185	20040726
EP 1654229	B1	20070509		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JF 2007500694	T	20070118	JF 2006-521803	20040726
AT 361911	T	20070615	AT 2004-749185	20040726
ES 2285495	T3	20071116	ES 2004-4749185	20040726
US 2007112022	A1	20070517	US 2006-566799	20060130
PRIORITY APPL. INFO.:			SE 2003-2155	A 20030731
			SE 2004-1420	A 20040603
			WO 2004-SE1149	W 20040726

OTHER SOURCE(S): CASREACT 142:197888; MARPAT 142:197888
GI



I



II

AB Title compds. represented by the formula I [wherein A = absent or (CH₂)₂;
R1 = (un)substituted carbonylamino, carbonylalkoxy, (hetero)aryl, etc.;

R2 = Ph, heteroaryl or cycloalkyl; R3 = H or alkyl; X = SO₂NR₄R₅ or NR₆SO₂R₇;
R7 = (hetero)aryl, (cyclo)alkyl, heterocyclyl or NR₈R₉; R4, R8 = (hetero)aryl, (cyclo)alkyl or heterocyclyl; R5, R6, R9 = independently H or alkyl; or R8R9 = (hetero)cyclic ring; n = 1-3; and pharmaceutically acceptable salts or solvates thereof] were prepared as modulators of chemokine receptor. For example, II was given in a multi-step synthesis starting from the reaction of N-benzoyloxycarbonyl-4-formylpiperidine with malonic acid. II showed inhibition of human CCR5 receptor with a Pic₅₀ value of 8.1. Thus, I and their pharmaceutical compns. are useful for

the treatment of CCR5 mediated diseases (no data).

IT 835876-90-9P 835876-91-0P 835876-92-1P
835876-93-2P 835876-94-3P 835876-95-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of piperidine derivs. as chemokine receptor CCR5 modulators)

RN 835876-90-9 CAPLUS

CN 4-Piperidineethanesulfonamide, 1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-N-(2-methoxyethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 835876-91-0 CAPLUS

CN 4-Piperidineethanesulfonamide, N-cyclopropyl-1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 835876-92-1 CAPLUS

CN 4-Piperidineethanesulfonamide, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 835876-93-2 CAPLUS

CN 4-Piperidineethanesulfonamide, N-cyclopentyl-1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 835876-94-3 CAPLUS

CN 4-Piperidineethanesulfonamide, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-N-(2-methoxyethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 835876-95-4 CAPLUS

CN 4-Piperidineethanesulfonamide, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-N,N-diethyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2005:74101 CAPLUS
DOCUMENT NUMBER: 142:176694
TITLE: Preparation of piperidine or 8-aza-bicyclo[3.2.1]oct-3-

INVENTOR(S): Brown, Dearg; Cumming, John; Tucker, Howard
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007629	A1	20050127	WO 2004-SE1135	20040714
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MU, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1648871	A1	20060426	EP 2004-749171	20040714
EP 1648871	B1	20071017		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007528867	T	20071018	JP 2006-520141	20040714
AT 375981	T	20071115	AT 2004-749171	20040714
US 2006205769	A1	20060914	US 2006-564509	20060111
PRIORITY APPLN. INFO.:			SE 2003-2090	A 20030716
			WO 2004-SE1135	W 20040714

OTHER SOURCE(S): CASREACT 142:176694; MARPAT 142:176694
GI

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. represented by the formula I (wherein A = absent or (CH2)2; R1 = (un)substituted carbonylamino, carbonylalkoxy, (hetero)aryl, etc.;

R2 = Ph, heteroaryl or cycloalkyl; R3 = H or alkyl; R4 = heterocyclyl; n = 1-3; and pharmaceutically acceptable salts or solvates thereof) were prepared as modulators of chemokine receptor. For example, II was given


in a multi-step synthesis starting from the reaction of N-benzoyloxycarbonyl-4-formylpiperidine with malonic acid. II showed inhibition of the binding of MIP-1a with a Pic50 value of 7.4. Thus, I and their pharmaceutical compns. are useful for the treatment of CCR5 mediated diseases (no data).

IT 833490-55-4P 833490-62-3P 833490-85-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RN 833490-55-4 CAPLUS
CN Piperidine, 4-[(1R)-1-(3,5-difluorophenyl)-3-[4-[2-(4-piperidinylsulfonyl)ethyl]-1-piperidinyl]propyl]-1-(methylsulfonyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 833490-62-3 CAPLUS
CN Piperidine, 1-[(1R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-(4-piperidinylsulfonyl)ethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 833490-95-0 CAPLUS
CN Piperazine, 1-[(1R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl[ethyl]sulfonyl]-4-ethyl- (CA INDEX NAME)
INDEX NAME

Absolute stereochemistry.

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IT 833490-56-5P 833490-57-6P 833490-58-7P
833490-59-8P 833490-60-1P 833490-61-2P
833490-63-4P 833490-64-5P 833490-65-6P
833490-66-7P 833490-67-8P 833490-68-9P
833490-69-0P 833490-70-3P 833490-71-4P
833490-72-5P 833490-73-6P 833490-74-7P
833490-75-8P 833490-76-9P 833490-77-0P
833490-78-1P 833490-79-2P 833490-80-5P
833490-81-6P 833490-82-7P 833490-83-8P
833490-84-9P 833490-86-1P 833490-87-2P
833490-88-3P 833490-89-4P 833490-90-7P
833490-91-8P 833490-92-9P 833490-93-0P
833490-94-1P 833490-95-2P 833490-96-3P
833490-97-4P 833490-98-5P 833490-99-6P
833491-00-2P 833491-01-3P 833491-02-4P
833491-03-5P 833491-04-6P 833491-05-7P
833491-06-8P 833491-07-9P 833491-08-0P
833491-09-1P 833491-10-4P 833491-11-5P
833491-12-6P 833491-13-7P 833491-14-8P
833491-15-9P 833491-16-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperidine derivs. as chemokine receptor modulators)
RN 833490-56-5 CAPLUS
CN Piperidine,
4-[(1R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-piperidinyl[ethyl]sulfonyl]-1-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-57-6 CAPLUS
CN Piperidine, 1-acetyl-4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-58-7 CAPLUS
CN Piperidine, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833490-59-8 CAPLUS
CN Piperidine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 833490-60-1 CAPLUS
CN Piperidine, 1-acetyl-4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-61-2 CAPLUS
CN Piperidine, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-1-(trifluoromethyl)sulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-63-4 CAPLUS
CN Piperidine, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-64-5 CAPLUS
CN 1H-1,4-Diazepine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]hexahydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-65-6 CAPLUS
CN 4-Piperidinol, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-66-7 CAPLUS
CN Thiomorpholine, 4-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-67-8 CAPLUS
CN Pyrrolidine, 1-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-70-3 CAPLUS
CN 3-Pyrrolidinol, 1-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-71-4 CAPLUS
CN Morpholine, 4-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-68-9 CAPLUS
CN Piperazine, 1-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-69-0 CAPLUS
CN Pyridine, 1-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-1,2,3,6-tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-72-5 CAPLUS
CN Pyrrolidine, 1-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-3-fluoro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-73-6 CAPLUS
CN Pyrrolidine, 1-[[2-[[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-74-7 CAPLUS
CN 1H-Pyrrole, 1-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)-2,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-75-8 CAPLUS
CN Azetidine, 1-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-78-1 CAPLUS
CN Piperidine, 1-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)-4,4-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-79-2 CAPLUS
CN 8-Oxa-3-azabicyclo[3.2.1]octane, 3-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-76-9 CAPLUS
CN 1,4-Oxazepine, 4-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)hexahydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-77-0 CAPLUS
CN Piperazine, 1-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-80-5 CAPLUS
CN 2-Pyrrolidinamine, 1-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)-N-formyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-81-6 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-([2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-82-7 CAPLUS
CN Pyrrolidine, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-2-methoxymethyl)-, (2S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 833490-83-8 CAPLUS
CN 4-Piperidinemethanol, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-2,6-dimethyl-, (3R,5S)- (CA INDEX NAME)]piperazine

Absolute stereochemistry.




RN 833490-87-2 CAPLUS
CN 3-Pyrrolidinamine, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-N,N-dimethyl-, (3S)- (CA INDEX NAME)]piperazine

Absolute stereochemistry.




RN 833490-88-3 CAPLUS
CN Piperazine, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-4-(2-methoxyethyl)-, (2R)- (9CI) (CA INDEX NAME)]pyrrolidine

Absolute stereochemistry.




RN 833490-84-9 CAPLUS
CN Morpholine, 4-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-3,5-dimethyl-, (3R,5S)- (CA INDEX NAME)]piperidine

Absolute stereochemistry.




RN 833490-86-1 CAPLUS
CN Piperazine, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-2,6-dimethyl-, (3R,5S)- (CA INDEX NAME)]piperidine

Absolute stereochemistry.




RN 833490-89-4 CAPLUS
CN 2-Pyrrolidinamine, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-N-formyl-, (2R)- (9CI) (CA INDEX NAME)]piperazine

Absolute stereochemistry.




RN 833490-90-7 CAPLUS
CN Pyrrolidine, 1-[(2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinylethylsulfonyl}-2-methoxymethyl-, (2R)- (9CI) (CA INDEX NAME)]piperazine

Absolute stereochemistry.




RN 833490-91-8 CAPLUS
CN Piperazine, 1-[(2-[1-[(3R)-3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl]-4-piperidinyl]ethyl)sulfonyl]-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-92-9 CAPLUS
CN 3-Piperidinecarboxamide, 1-[(2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 833490-95-2 CAPLUS
CN 4-Piperidineethanol, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




```

RN      833490-96-3  CAPLUS
CN      1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[2-[1-((3R)-3-(3,5-difluorophenyl)-3-
      (4-(methylsulfonyl)phenyl)propyl]-4-piperidinyl)ethyl]sulfonyl]decane (CA
      INDEX NAME)


```

Absolute stereochemistry.




RN 833490-93-0 CAPLUS
CN Acetamide, N-[1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-94-1 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methanesulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-97-4 CAPLUS
CN 3-Azetidinol, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-98-5 CAPLUS
CN 1-piperazineethanol, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833490-99-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-00-2 CAPLUS
CN Piperazine, 1-acetyl-4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-03-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-04-6 CAPLUS
CN 3-Piperidineacetonitrile, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-01-3 CAPLUS
CN Pyrrolidine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-02-4 CAPLUS
CN 1H-1,4-Diazepine, 1-acetyl-4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]hexahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-05-7 CAPLUS
CN 1-Piperazinepropanol, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-06-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-07-9 CAPLUS
CN Pyrrolidine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-3-fluoro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-08-0 CAPLUS
CN 2-Pyrrolidinecarboxylic acid, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, (2S)- (CA INDEX NAME)



RN 833491-11-5 CAPLUS
CN Piperazine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-4-(ethylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 833491-12-6 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 833491-09-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-10-4 CAPLUS
CN Piperidine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-13-7 CAPLUS
CN Piperazine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-4-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-14-8 CAPLUS
CN Piperazine, 1-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-4-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-15-9 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[2-[1-(3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-16-0 CAPLUS
CN Piperidine, 1-[[2-[1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833491-32-0 CAPLUS
CN 4-Piperidineethanesulfonyl chloride, 1-[[3-(3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT




IT 833491-27-3P 833491-28-4P 833491-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of piperidine derivs. as chemokine receptor modulators)

RN 833491-27-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 833491-28-4 CAPLUS



CN 1-Piperidinecarboxylic acid, 4-[[2-[1-((3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-4-piperidinyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2004:546479 CAPLUS
DOCUMENT NUMBER: 141:106374
TITLE: A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5
INVENTOR(S): Cumming, John; Faull, Alan; Fielding, Colin; Oldfield,
PATENT ASSIGNEE(S): John; Tucker, Howard
SOURCE: AstraZeneca AB, Swed.
PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056773	A1	20040708	WO 2003-SE2008	20031218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			
TG	CA 2508624	A1	20040708	CA 2003-2508624
	AU 2003288856	A1	20040714	AU 2003-288856
	EP 1572650	A1	20050914	EP 2003-781235
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	BR 2003017459	A	20051116	BR 2003-17459
	CN 1732153	A	20060208	CN 2001-80107833
	JP 2006514107	T	20060427	JP 2005-502630
	IN 2005DN02442	A	20070406	IN 2005-DN2442
	MX 2005PA06381	A	20050829	MX 2005-PA6381
	US 2006189650	A1	20060824	US 2005-539859
	NO 2005003539	A	20050920	NO 2005-3539
	ZA 2005004616	A	20060329	ZA 2005-4616
PRIORITY APPLN. INFO.:			SE 2002-3821	A 20021220
			SE 2003-499	A 20030224
			SE 2003-1425	A 20030515
			WO 2003-SE2008	W 20031218

OTHER SOURCE(S): MARPAT 141:106374
GI



AB The invention relates to a preparation of novel piperidine derivs. of formula I (wherein: A is absent or (CH₂)₂; R₁ is alkyl, C(O)NH-alkyl, or CO₂-alkyl, etc.; R₂ is alkyl, Ph, heteroaryl, or cycloalkyl; R₃ is H or alkyl; R₄ is (hetero)aryl or (cyclo)alkyl; X is O or S(O)₀₋₂), useful as modulators of chemokine receptor CCR5. The invention compds. are claimed to be useful for the treatment of CCR5-mediated diseases such as autoimmune, inflammatory, or proliferative diseases. The invented compds. are also

of value in inhibiting the entry of viruses (such as HIV) into target cells (no biol. data). The ability of the invention compds. to inhibit the binding of RANTES and MIP-1α was assessed (certain compds. of formula I have IC₅₀ < 50 μM). For instance, Pic50 (neg. log of the IC₅₀ result) for piperidine derivative II was determined as 6.91 (table

XV).

IT 718610-20-9P 718610-31-4P 718610-40-3P

718610-42-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel piperidine derivs. as modulators of chemokine receptor


CCR5)

RN 718610-20-9 CAPLUS

CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-

(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 718610-33-4 CAPLUS

CN Acetonitrile, 4-[(2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 718610-40-3 CAPLUS

CN Acetic acid, 4-[(2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 718610-42-5 CAPLUS

CN Acetic acid, 4-[(2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 718610-14-1P 718610-16-3P 718610-18-5P

718610-22-1P 718610-24-3P 718610-27-6P

718610-29-8P 718610-32-3P 718610-35-6P

718610-36-7P 718610-38-9P 718610-43-6P

718610-44-7P 718610-45-8P 718610-47-0P

718610-48-1P 718610-49-2P 718610-50-5P

718611-22-4P 718611-25-7P 718611-26-8P

718611-27-9P 718611-28-0P 718611-29-1P

718611-30-4P 718611-31-5P 718611-32-6P

718611-33-7P 718611-34-8P 718611-35-9P

718611-38-2P 718611-39-3P 718611-40-6P

718611-41-7P 718611-42-8P 718611-43-9P

718611-44-0P 718611-45-1P 718611-46-2P

718611-47-3P 718611-48-4P 718611-49-5P

718611-50-8P 718611-51-9P 718611-52-0P

718611-53-1P 718611-54-2P 718611-55-3P

718611-56-4P 718611-57-5P 718611-58-6P

718611-59-7P 718611-60-0P 718611-61-1P

718611-62-2P 718611-63-3P 718611-64-4P

718611-65-5P 718611-66-6P 718611-67-7P

718611-68-8P 718611-69-9P 718611-70-2P

718611-71-3P 718611-72-4P 718611-73-5P

718611-74-6P 718611-75-7P 718611-76-8P

718611-77-9P 718611-78-0P 718611-79-1P

718611-80-4P 718611-81-5P 718611-82-6P

718611-83-7P 718611-84-8P 718611-85-9P

718611-86-0P 718611-87-1P 718611-88-2P

718611-89-3P 718611-90-6P 718611-91-7P

718611-92-8P 718611-93-9P 718611-94-0P

718611-95-1P 718611-96-2P 718611-97-3P

718611-98-4P 718611-99-5P 718612-00-1P

718612-01-2P 718612-02-3P 718612-03-4P

718612-04-5P 718612-05-6P 718612-06-7P

718612-07-8P 718612-08-9P 718612-09-0P

718612-10-3P 718612-11-4P 718612-12-5P

718612-13-6P 718612-14-7P 718612-15-8P

718612-16-9P 718612-17-0P 718612-18-1P

718612-19-2P 718612-20-5P 718612-21-6P

718612-22-7P 718612-23-8P 718612-24-9P

718612-25-0P 718612-26-1P 718612-27-2P

718612-28-3P 718612-29-4P 718612-30-7P

718612-31-8P 718612-32-9P 718612-33-0P

718612-34-1P 718612-35-2P 718612-36-3P

718612-37-4P 718612-38-5P 718612-39-6P

718612-43-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel piperidine derivs. as modulators of chemokine

receptor: CCR5)

RN 718610-14-1 CAPLUS


CN Piperazine, 1-(methylsulfonyl)-4-[3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)



RN 718610-16-3 CAPLUS


CN Piperidine,

4-[2-[(4-fluorophenyl)sulfonyl]ethyl]-1-[3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)




RN 718610-18-5 CAPLUS
CN Benzamide,
4-chloro-N-([1S]-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]et
hy]-1-piperidinyl]-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718610-22-1 CAPLUS
CN Piperazine, 1-[3-[4-(2-[(4-fluorophenyl)sulfonyl]ethyl)-1-piperidinyl]-1-phenylpropyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 718610-24-3 CAPLUS
CN Piperidine, 4-[[1R]-1-(3,5-difluorophenyl)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]propyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 718610-35-6 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methanesulfonyl)phenyl]propyl]-4-(2-{[4-(1H-tetrazol-5-ylmethoxy)phenyl]sulfonyl}ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718610-36-7 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718610-27-6 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-3-[4-{2-[(4-{(methylsulfonyl)oxy}phenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-9CI] (CA INDEX NAME)

Absolute stereochemistry.



RN 718610-29-8 CAPLUS
CN Piperidine,
1-(methylsulfonyl)-4-((1R)-1-phenyl-3-[4-[2-[[4-(1H-tetrazol-5-
yl)phenyl]sulfonyl]ethyl]-1-piperidinyl]propyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718610-32-3 CAPLUS
CN Acetamide, 2-[4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidiny]ethyl)sulfonyl]phenoxy]-
(CA

Cn1nc2ccc(cc2n1)S(=O)(=O)CCN3CCCCC3CCN(Rc4ccc(cc4)C(=O)C)c5cc(F)cc(F)c5

RN 718610-38-9 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methanesulfonyl)phenyl]propyl]-4-[2-[[4-(1-methyl-1H-tetrazol-5-yl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 718610-43-6 CAPLUS
CN Acetamide, 2-[4-{[2-{1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl}phenoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

P


RN 718610-44-7 CAPLUS
 CN Acetamide, 2-[4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718610-45-8 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 718610-47-0 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 718610-48-1 CAPLUS
 CN 2-Butenedioic acid (2Z)-, compd. with 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidine (9CI) (CA INDEX NAME)

CM 1

CRN 718610-20-9
 CMF C30 H35 F2 N O6 S3


Absolute stereochemistry.



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 718610-49-2 CAPLUS
 CN Butanedioic acid, compd. with 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidine (9CI) (CA INDEX NAME)

CM 1

CRN 718610-20-9
 CMF C30 H35 F2 N O6 S3

Absolute stereochemistry.



CM 2

CRN 110-15-6
 CMF C4 H5 O4


HO₂C-CH₂-CH₂-CO₂H

RN 718610-50-5 CAPLUS
 CN Propanedioic acid, compd. with 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidine (9CI) (CA INDEX NAME)

CM 1

CRN 718610-20-9
CMP C30 H35 F2 N O6 S3

Absolute stereochemistry.




CM 2


CRN 141-82-2
CMP C3 H4 O4

HO₂C-CH₂-CO₂H


RN 718611-22-4 CAPLUS
CN Piperazine, 1-[3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-4-(phenylsulfonyl)- (CA INDEX NAME)




RN 718611-25-7 CAPLUS
CN Piperazine, 1-[3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-4-phenyl- (CA INDEX NAME)




RN 718611-30-4 CAPLUS
CN Piperidine, 4-[3-[4-[2-[[4-(4-chlorophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-((trifluoromethyl)sulfonyl)- (9CI) (CA INDEX NAME)




RN 718611-31-5 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[1-phenyl-3-[4-[2-(phenylsulfonyl)ethyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




RN 718611-32-6 CAPLUS
CN Piperidine, 4-[3-[4-[2-[[4-(4-methylphenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 718611-33-7 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[1-phenyl-3-[4-[2-[[4-(trifluoromethyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




RN 718611-26-8 CAPLUS
CN Piperazine, 1-(ethylsulfonyl)-4-[3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)




RN 718611-27-9 CAPLUS
CN Piperazine, 1-[3-[4-[2-[[4-(4-fluorophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-4-phenyl- (CA INDEX NAME)




RN 718611-28-0 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)




RN 718611-29-1 CAPLUS
CN Piperidine, 4-[3-[4-[2-[[4-(4-chlorophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 718611-34-8 CAPLUS
CN Piperidine, 4-[3-[4-[2-[[4-(4-methoxyphenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 718611-35-9 CAPLUS
CN Piperidine, 4-[3-[4-[2-[[4-(4-cyanophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 718611-38-2 CAPLUS
CN Piperazine, 1-[(1R)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-39-3 CAPLUS
CN Piperazine, 1-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-40-6 CAPLUS
CN Piperidine, 4-[(1R)-3-[4-{2-[(4-fluorophenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 718611-41-7 CAPLUS
CN Piperidine, 4-[(1S)-3-[4-{2-[(4-fluorophenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 718611-42-8 CAPLUS
CN Piperazine, 1-(methylsulfonyl)-4-{1-phenyl-3-[4-{2-[(phenylsulfonyl)ethyl]-1-piperidinyl}propyl]}- (CA INDEX NAME)




RN 718611-48-4 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-methylphenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 718611-49-5 CAPLUS
CN Piperazine, 1-[1-phenyl-3-[4-{2-[(4-(trifluoromethyl)phenyl)sulfonyl]ethyl}-1-piperidinyl]propyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 718611-50-8 CAPLUS
CN Piperazine, 1-[1-phenyl-3-[4-{2-[(phenylsulfonyl)ethyl]-1-piperidinyl]propyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 718611-51-9 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-chlorophenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-(methylsulfonyl)- (CA INDEX NAME)




RN 718611-43-9 CAPLUS
CN Piperazine, 1-[1-phenyl-3-[4-{2-[(phenylsulfonyl)ethyl]-1-piperidinyl}propyl]-4-(phenylsulfonyl)- (CA INDEX NAME)




RN 718611-44-0 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-methoxyphenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-(methylsulfonyl)- (CA INDEX NAME)




RN 718611-45-1 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-methoxyphenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 718611-46-2 CAPLUS
CN Piperazine, 1-(methylsulfonyl)-4-{1-phenyl-3-[4-{2-[(4-(trifluoromethyl)phenyl)sulfonyl]ethyl}-1-piperidinyl]propyl]}- (CA INDEX NAME)




RN 718611-47-3 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-methylphenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-(methylsulfonyl)- (CA INDEX NAME)




RN 718611-52-0 CAPLUS
CN Piperazine, 1-(phenylsulfonyl)-4-{1-phenyl-3-[4-{2-[(4-(trifluoromethyl)phenyl)sulfonyl]ethyl}-1-piperidinyl]propyl]}- (CA INDEX NAME)




RN 718611-53-1 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-fluorophenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 718611-54-2 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-chlorophenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)



RN 718611-55-3 CAPLUS
CN Piperazine, 1-[3-[4-{2-[(4-methylsulfonyl)phenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 718611-56-4 CAPLUS
CN 1-Piperidinesulfonamide, N,N-dimethyl-4-[3-[4-{2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl]}- (CA INDEX NAME)



RN 718611-57-5 CAPLUS
CN Benzenesulfonamide, 4-([2-[1-[3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]-4-piperidinyl]ethyl)sulfonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂

RN 718611-58-6 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[3-[4-[2-[(4-(methylsulfonyl)methyl]phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—Me

RN 718611-59-7 CAPLUS



RN 718611-63-3 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-3-[4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-[3-(trifluoromethyl)phenyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 718611-64-4 CAPLUS
CN Piperidine, 4-[(1R)-1-[3,5-difluorophenyl]-3-[4-[2-[(4-methoxyphenyl)sulfonyl]ethyl]-1-piperidinyl]propyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Benzenesulfonamide, 4-([2-[1-[3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]-4-piperidinyl]ethyl)sulfonyl]- (CA INDEX NAME)



RN 718611-60-0 CAPLUS
CN Piperidine, 4-[3-[4-[2-[(4-hydroxyphenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 718611-61-1 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[3-[4-[2-[(4-(methylsulfonyl)oxy)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)




RN 718611-62-2 CAPLUS
CN 1-Piperidinesulfonamide, 4-[(1R)-1-(3,4-difluorophenyl)-3-[4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]propyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-65-5 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-3-[4-[2-[(4-(2-methyl-2H-tetrazol-5-yl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 718611-66-6 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-3-[4-[2-[(4-(2-methyl-2H-tetrazol-5-yl)methoxy]phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



RN 718611-67-7 CAPLUS
CN Piperidine,
1-(methylsulfonyl)-4-((1R)-3-[4-[2-[[4-((1-methyl-1H-tetrazol-5-yl)methoxy]phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




RN 718611-68-8 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-69-9 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)




RN 718611-73-5 CAPLUS
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 718611-74-6 CAPLUS
CN Piperidine, 4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-[(3R)-3-[4-(methylsulfonyl)phenyl]-3-(2-thienyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 718611-75-7 CAPLUS
CN Piperidine, 4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-[(3R)-3-[4-(methylsulfonyl)phenyl]-3-(3-thienyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 718611-70-2 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[[4-(4-fluorophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-71-3 CAPLUS
CN Butanamide, 4,4,4-trifluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-72-4 CAPLUS
CN Cyclobutanecarboxamide, 3,3-difluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-76-8 CAPLUS
CN Piperidine,
1-[(3S)-3-[4-(methylsulfonyl)phenyl]-3-phenylpropyl]-4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-77-9 CAPLUS
CN Piperidine, 4-[2-[[4-(4-fluorophenyl)sulfonyl]ethyl]-1-[(3S)-3-[4-(methylsulfonyl)phenyl]-3-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-78-0 CAPLUS
CN Piperidine, 1-[(3R)-3-[5-chloro-2-thienyl]-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-79-1 CAPLUS
 CN Piperidine, 1-[(3R)-3-(4-chloro-2-thienyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-80-4 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(4-fluorophenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-81-5 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-(phenylsulfonyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-82-6 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(4-methoxyphenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-83-7 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(4-nitrophenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-84-8 CAPLUS
 CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(4-(trifluoromethoxy)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-85-9 CAPLUS
 CN Acetamide, N-[4-[(2-[(1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl)ethyl]sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-86-0 CAPLUS
 CN Benzenamine, 4-[(2-[(1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl)ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-87-1 CAPLUS
CN Methanesulfonamide, N-[4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-88-2 CAPLUS
CN Urea, N-[4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]phenyl]-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-89-3 CAPLUS
CN Phenol, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-90-6 CAPLUS
CN Phenol, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 718611-91-7 CAPLUS
CN Phenol, 4-[[2-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B

RN 718611-92-8 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(1-methyl-2H-tetrazol-5-yl)methoxy]phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B


RN 718611-93-9 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(1-methyl-1H-tetrazol-5-yl)methoxy]phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-94-0 CAPLUS
CN Piperidine, 1-[(methylsulfonyl)-4-[(1R)-1-phenyl-3-[4-[(phenylmethyl)sulfonylmethyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 718611-95-1 CAPLUS
CN Piperidine, 4-[[[4-(methoxyphenyl)methyl]sulfonylmethyl]-1-[(3R)-3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 718611-96-2 CAPLUS
CN Piperidine, 4-[(1R)-3-[4-[[[4-(methylphenyl)methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 718612-00-1 CAPLUS
CN Piperazine, 1-[(methylsulfonyl)-4-[(1S)-3-[4-[[[4-(methylsulfonyl)phenyl]methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)]

Absolute stereochemistry.




RN 718612-01-2 CAPLUS
CN Piperazine, 1-[(1S)-3-[4-[[[4-(methylsulfonyl)phenyl]methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]-4-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)]

Absolute stereochemistry.




RN 718612-02-3 CAPLUS
CN Piperidine, 4-[(1R)-3-[4-[[[4-(cyanophenyl)methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)]




RN 718611-97-3 CAPLUS
CN Piperidine, 4-[(1R)-3-[4-[[[4-(4-fluorophenyl)methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 718611-98-4 CAPLUS
CN Piperidine, 1-[(methylsulfonyl)-4-[(1R)-3-[4-[[[4-(methylsulfonyl)phenyl]methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 718611-99-5 CAPLUS
CN Piperidine, 4-[(1R)-1-(3,5-difluorophenyl)-3-[4-[[[4-(methylsulfonyl)phenyl]methyl]sulfonylmethyl]-1-piperidinyl]propyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

Absolute stereochemistry.




RN 718612-03-4 CAPLUS
CN Benzamide, 4-[[[1-[(3R)-3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]-4-piperidinyl]methyl]sulfonylmethyl]- (CA INDEX NAME)]

Absolute stereochemistry.




RN 718612-04-5 CAPLUS
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-[[[4-(methylsulfonyl)phenyl]methyl]sulfonylmethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)]

Absolute stereochemistry.




RN 718612-05-6 CAPLUS
CN Piperidine, 1-[(3R)-3-[3,5-difluorophenyl]-3-[4-[(methylsulfonyl)phenyl]propyl]-4-[[[4-(methylsulfonyl)phenyl]methyl]sulfonylmethyl]- (CA INDEX NAME)]

Absolute stereochemistry.




RN 718612-06-7 CAPLUS
CN Piperidine, 1-({(3S)-3-(4-(methylsulfonyl)phenyl)-3-phenylpropyl)-4-
((phenylmethyl)sulfonylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-07-8 CAPLUS
CN Piperidine, 1-({(3R)-3-(3,5-difluorophenyl)-3-[4-(
(methylsulfonyl)phenyl]propyl)-4-[[4-(methoxyphenyl)methyl]sulfonylmethy
l]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-08-9 CAPLUS
CN Benzonitrile, 4-([1-({(3R)-3-(3,5-difluorophenyl)-3-[4-(
(methylsulfonyl)phenyl]propyl)-4-piperidinyl]methyl)sulfonylmethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 718612-09-0 CAPLUS
CN Benzanide, 4-([1-({(3R)-3-(3,5-difluorophenyl)-3-[4-(
(methylsulfonyl)phenyl]propyl)-4-piperidinyl]methyl)sulfonylmethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 718612-10-3 CAPLUS
CN Pyridine, 5-([1-({(3R)-3-(3,5-difluorophenyl)-3-[4-((methylsulfonyl)phenyl)methyl]sulfonylmethyl]-1-piperidinyl]propyl)-2-(
(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-11-4 CAPLUS
CN Pyridine, 5-([1-({(3R)-3-(3,5-difluorophenyl)-3-[4-(
(methylsulfonyl)phenyl]propyl)-4-piperidinyl]methyl)sulfonylmethyl]-2-(
(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-12-5 CAPLUS
CN Pyridine, 2-([1-({(3R)-3-(3,5-difluorophenyl)-3-[4-(
(methylsulfonyl)phenyl]propyl)-4-piperidinyl]methyl)sulfonylmethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 718612-13-6 CAPLUS
CN Pyridine, 4-([1-({(3R)-3-(3,5-difluorophenyl)-3-[4-(
(methylsulfonyl)phenyl]propyl)-4-piperidinyl]methyl)sulfonylmethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 718612-14-7 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(methylsulfonyl)methyl]phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-15-8 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(methylsulfonyl)methyl]phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-18-1 CAPLUS
CN Piperidine, 4-[2-[(3-chlorophenyl)sulfonyl]ethyl]-1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-19-2 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(trifluoromethyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-16-9 CAPLUS
CN Pyridine, 5-[(1S)-1-(3,5-difluorophenyl)-3-[4-[(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]propyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-17-0 CAPLUS
CN Piperidine, 1-[(3R)-3-(3-chloro-5-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-20-5 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(trifluoromethyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-21-6 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[[4-[(trifluoromethyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-22-7 CAPLUS
CN Piperidine, 1-([3-(3-(methylsulfonyl)phenyl)-3-phenylpropyl]-4-[2-([4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)



RN 718612-23-8 CAPLUS
CN Phenol, 3-([2-([1-((3R)-3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl]-4-piperidinyl)ethyl)sulfonyl]-4-methylbenzenesulfonyl (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



F


RN 718612-26-1 CAPLUS
CN Piperidine, 1-([3-(3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-([3,4-dimethoxyphenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-27-2 CAPLUS
CN Piperidine, 1-([3-(3-(3,5-difluorophenyl)-3-(tetrahydro-2H-pyran-4-yl)propyl]-4-[2-([4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 718612-24-9 CAPLUS
CN Phenol, 3-([2-([1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl)ethyl)sulfonyl]-methanesulfonyl (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 718612-25-0 CAPLUS
CN Phenol, 3-([2-([1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl)ethyl)sulfonyl]-4-methylbenzenesulfonyl (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




RN 718612-28-3 CAPLUS
CN Piperidine, 1-([3-(3-(3,5-difluorophenyl)-3-(tetrahydro-2H-thiopyran-4-yl)propyl]-4-[2-([4-(methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-29-4 CAPLUS
CN Piperidine, 4-[2-([4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-([3-(3-phenyl)-3-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-30-7 CAPLUS
CN Piperidine, 4-[2-([3-chloro-4-fluorophenyl)sulfonyl]ethyl]-1-([3-(3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-31-8 CAPLUS
CN Piperidine, 4-[(1R)-3-[4-[2-(cyclohexylsulfonyl)ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-32-9 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-3-[4-[2-(methylsulfonyl)ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-33-0 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-1-phenyl-3-[4-[2-(3-pyridinylsulfonyl)ethyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-37-4 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-38-5 CAPLUS
CN Piperidine, 1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-[2-[(1-methyl-1H-imidazol-2-yl)sulfonyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-34-1 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[(1R)-3-[4-[2-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-35-2 CAPLUS
CN Piperidine, 4-[(1R)-3-[4-[2-[(1-methyl-1H-imidazol-2-yl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-36-3 CAPLUS
CN Pyridine, 3-[12-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-39-6 CAPLUS
CN Pyridine, 5-[12-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]ethyl]sulfonyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-43-2 CAPLUS
CN Piperidine, 1-(methylsulfonyl)-4-[1-phenyl-3-[4-[2-[(1H-tetrazol-5-yl)sulfonyl]ethyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




IT 718610-28-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of novel piperidine derivs. as modulators of chemokine
 receptor
 Ccr5)
 RN 718610-28-7 CAPLUS
 CN Piperidine, 4-[(1R)-3-{4-[(2-{[(4-hydroxyphenyl)sulfonyl]ethyl}-1-
 piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 718610-15-2P 718610-19-6P 718610-23-2P
 718610-30-1P 718610-66-3P 718610-67-4P
 718610-69-6P 718611-16-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of novel piperidine derivs. as modulators of chemokine
 receptor
 Ccr5)
 RN 718610-15-2 CAPLUS
 CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-[2-[(4-
 (methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)



RN 718610-19-6 CAPLUS
 CN 1-Piperidinepropanamine, 4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-
 α-phenyl-, (αS)- (CA INDEX NAME)




RN 718610-67-4 CAPLUS
 CN 1-Propanone, 3-[4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-
 piperidinyl]-1-phenyl- (CA INDEX NAME)



RN 718610-69-6 CAPLUS
 CN 1-Piperidinepropanol, 4-[2-[(4-(4-fluorophenyl)sulfonyl]ethyl]-α-phenyl-
 , (αS)- (CA INDEX NAME)


Absolute stereochemistry.




RN 718611-16-6 CAPLUS
 CN Carbamic acid,
 [(1S)-3-[4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-1-
 piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

Absolute stereochemistry.




RN 718610-23-2 CAPLUS
 CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-[2-[(4-
 fluorophenyl)sulfonyl]ethyl]- (CA INDEX NAME)




RN 718610-30-1 CAPLUS
 CN Piperidine,
 4-[(1R)-3-[4-[2-[(4-cyanophenyl)sulfonyl]ethyl]-1-piperidinyl]-
 1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 718610-66-3 CAPLUS
 CN 1-Piperidinepropanol, 4-[2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl]-
 α-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:2730 CAPLUS
DOCUMENT NUMBER: 140:71043
TITLE: Combination treatment for depression and anxiety by NK1 and NK3 antagonists
INVENTOR(S): Sobolov-Jaynes, Susan Beth; Lowe, John Adams, III; McLean, Stafford
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PFXKXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000355	A1	20031231	WO 2003-IB2516	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2004006135	A1	20040108	US 2003-386582	20030312
CA 2488311	A1	20031231	CA 2003-2488311	20030610
AU 2003239280	A1	20040106	AU 2003-239280	20030610
EP 1517708	A1	20050330	EP 2003-732858	20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011898	A	20050412	BR 2003-11898	20030610
JP 200553080	T	20051104	JP 2004-515136	20030610
MX 2005PA00260	A	20050411	MX 2005-PA260	20050103
PRIORITY APPLN. INFO.:			US 2002-389975P	P 20020619
			WO 2003-IB2516	W 20030610

OTHER SOURCE(S): MARPAT 140:71043
AB The invention discloses a method for treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an NK3 antagonist agent. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier.
a CNS-penetrant NK1 receptor antagonist and an NK3 antagonist.
IT 204642-49-9 204642-56-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK1 and NK3 antagonist combination treatment for depression and anxiety)
RN 204642-49-9 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-(phenylsulfonylmethyl)-1-piperidinyl]propyl]-, monohydrochloride, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2002:252956 CAPLUS
DOCUMENT NUMBER: 136:273215
TITLE: Combination of an NK-3 receptor antagonist and a CNS-penetrant NK-1 receptor antagonist for treating depression and anxiety
INVENTOR(S): Lowe, John Adams, III; McLean, Stafford; Sobolov-Jaynes, Susan Beth
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 65 pp.
CODEN: EPFXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1192952	A2	20020403	EP 2001-307657	20010910
EP 1192952	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2357901	A1	20020328	CA 2001-2357901	20010926
MX 2001PA09787	A	20020415	MX 2001-PA9787	20010927
BR 2001004345	A	20020521	BR 2001-4345	20010928
JP 2002338497	A	20021127	JP 2001-300136	20010928
PRIORITY APPLN. INFO.:			US 2000-236375P	P 20000928

OTHER SOURCE(S): MARPAT 136:273215
AB A composition for the treatment of anxiety or depression in a mammal, including a human, comprises (a) an NK-3 receptor antagonist or its salt, (b) a CNS-penetrant NK-1 receptor antagonist or its salt, and (c) a pharmaceutically acceptable carrier. When administered in combination, either as a single or as sep. pharmaceutical composition(s), the CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist, are presented in a ratio which is consistent with the manifestation of the desired effect. In particular, the ratio by weight of the CNS-penetrant NK-1 receptor antagonist and the NK-3 antagonist will suitably be between 0.001:1 to 1000:1, and especially between 0.01:1 and 100:1.
IT 204642-49-9 204642-56-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of NK3 receptor antagonist and CNS-penetrant NK1 receptor antagonist for treating depression and anxiety)
RN 204642-49-9 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-(phenylsulfonylmethyl)-1-piperidinyl]propyl]-, monohydrochloride, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 204642-56-8 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-(phenylsulfonylmethyl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 204642-56-8 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-(phenylsulfonylmethyl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:188046 CAPLUS
DOCUMENT NUMBER: 130:325069
TITLE: Syntheses and biological activities of chiral piperidines-tachykinin NK3 antagonists
AUTHOR(S): Chen, Michael H.; Chung, Fu-Zon; Roth, Bruce D.; Kuo, Be-Sheng; Atherton, James; Lee, Helen T.
CORPORATE SOURCE: Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SOURCE: Zhongguo Yao Li Xue Bao (1999), 20(3), 283-288
CODEN: CYLPDN; ISSN: 0253-9756
PUBLISHER: Kexue Chubanshe
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To develop nonpeptide tachykinin NK3 antagonists. Five tachykinin NK3 antagonists were synthesized. Receptor binding assay and oral absorption study were made. Thus, 4,4-disubstituted piperidine compds. showed stronger activities (IC50 = 5.9, 6.2, and 11 nmol·L⁻¹, resp.) than the monosubstituted ring compound (IC50 = 17 nmol·L⁻¹). 4-Ph and 4-phenylsulfonylmethyl compds. were more active than a 4-fluorobenzyl compound. All antagonists were found to be orally absorbable. A 4-Ph derivative had the best binding activity (IC50 = 5.9 nmol·L⁻¹) and the best AUC (2081 µg·h·L⁻¹).
IT 223719-96-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of chiral piperidines (tachykinin NK3 antagonists))
RN 223719-96-8 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-[(phenylsulfonyl)methyl]-1-piperidinyl]propyl]-, monohydrochloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:180863 CAPLUS
DOCUMENT NUMBER: 128:230385
TITLE: Preparation of 3-alkyl-3-phenylpiperidines as tachykinin NK3 antagonists
INVENTOR(S): Chen, Michael Huai Gu; Chung, Fu-Zon; Lee, Helen Tsenwhei
PATENT ASSIGNEE(S): Warner-Lambert Co., USA; Chen, Michael Huai Gu; Chung, Fu-Zon; Lee, Helen Tsenwhei
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811090	A2	19980319	WO 1997-US15443	19970902
WO 9811090	A3	19980522		
W: AL, AU, BA, BB, BG, BR, CA, CN, C2, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9741769	A	19980402	AU 1997-41769	19970902
ZA 9708304	A	19980324	ZA 1997-8304	19970915
US 6040316	A	20000321	US 1998-983584	19980122
US 2001037023	A1	20011101	US 2001-873889	20010604
US 6433178	B2	20020813		
US 2001073838	A1	20010417	US 2002-177386	20020621
US 6602886	B2	20030805		
PRIORITY APPLN. INFO.:			US 1996-26385P	P 19960916
			WO 1997-US15443	W 19970902
			US 1998-983584	A3 19980122
			US 1999-467431	B1 19991220
			US 2001-873889	A3 20010604


OTHER SOURCE(S): MARPAT 128:230385
GI

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB The title compds. I [R1 = alkyl, aryl, heteroaryl; R2 = H, OH, NH2, SH; R3 = aryl, arylsulfonylmethyl, heterocyclyl; R4 = 1-4 groups selected from halo, alkyl, OH, alkoxy; n = 2-6 and the methylene group may be replaced by O, N, S] were prepared. E.g.,
(3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-phenylpiperidin-1-yl]propyl]piperidin-1-yl)phenylmethanone hydrochloride was prepared and shown to be a potent and selective antagonist for the human tachykinin NK3 receptor.
IT 204642-49-9P 204642-56-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkylphenylpiperidines as tachykinin NK3 antagonists)
RN 204642-49-9 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-[(phenylsulfonyl)methyl]-1-piperidinyl]propyl]-, monohydrochloride, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 204642-56-8 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-[4-hydroxy-4-[(phenylsulfonyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1997:717923 CAPLUS
 DOCUMENT NUMBER: 128:3692
 TITLE: Fused imidazopyridine derivatives as antihyperlipidemic agents
 INVENTOR(S): Takatani, Muneo; Shibouta, Yumiko; Sugiyama, Yasuo; Kawamoto, Tetsuji
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 457 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740051	A1	19971030	WO 1997-JP1395	19970423
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2251625	A1	19971030	CA 1997-2251625	19970423
AU 9724048	A	19971112	AU 1997-24048	19970423
JP 10226699	A	19980825	JF 1997-105625	19970423
ZA 9703493	A	19981023	ZA 1997-3493	19970423
EP 915888	A1	19990519	EP 1997-919649	19970423
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
CN 1223659	A	19990721	CN 1997-193938	19970423
US 6235731	B1	20010522	US 1998-155889	19981008
PRIORITY APPLN. INFO.:			JP 1996-102303	A 19960424
			JP 1996-330801	A 19961211
			WO 1997-JP1395	W 19970423

OTHER SOURCE(S): MARPAT 128:3692
 G1



AB Novel compds. I (wherein ring Q is optionally substituted; one of R0, R1,


L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 and R2 = -Y0-Z0, and the others = H, halo, (un)substituted OH, (un)substituted hydrocarbyl, or acyl; Y0 = bond, (un)substituted bivalent hydrocarbon group; Z0 = basic group which may be bonded via O, N, CO, CS, SO2N(R3) (where R3 = H or (un)substituted hydrocarbyl), or S(O)n (where n = 0, 1, or 2); dotted line = optional pi bond] and salts thereof are disclosed. The compds. have excellent LDL receptor up-regulating, blood lipid-lowering, blood sugar-lowering, and diabetic complication-ameliorating activities. Examples include 178 synthetic examples, 79

ref. examples, and biol. data for approx. 20 selected compds. For instance, Et 5-thia-1,8b-diazaacenaphthylene-4-carboxylate underwent a sequence of DIBAL reductn. to an alc. (87%), oxidn. to an aldehyde and Wittig-based homologation to an acrylic acid deriv. (84%), amidation with 1-Boc-piperidin-4-ylmethylamine and deprotection (92%), N-alkylation with Ph(CH2)3Br (55%), and salification with methanolic HCl, to give the title compd. II.2HCl. In hamsters, II.2HCl reduced non-HDL cholesterol to

62.3% of control, and triglycerides to 67.0% of control.
 IT 198892-49-8P 198894-77-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused imidazopyridine derivs. as antihyperlipidemic agents)

RN 198892-49-8 CAPLUS
 CN 5-Thia-1,8b-diazaacenaphthylene, 4-[2-[[[1-(3-phenylpropyl)-4-piperidinyl]methyl]sulfonyl]ethenyl]-, dihydrochloride, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● 2 HCl

RN 198894-77-8 CAPLUS
 CN 5-Thia-1,8b-diazaacenaphthylene, 4-[2-[[[1-(3-phenylpropyl)-4-piperidinyl]methyl]sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 18:20:41 ON 31 JAN 2008)

FILE 'REGISTRY' ENTERED AT 18:20:50 ON 31 JAN 2008

L1 STRUCTURE UPLOADED

L2 16 S L1

L3 260 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:21:22 ON 31 JAN 2008

L4 9 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

53.37

231.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.20

-7.20

STN INTERNATIONAL LOGOFF AT 18:26:55 ON 31 JAN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:00:17 ON 31 JAN 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:00:27 ON 31 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1

DICTIONARY FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10564509.str



chain nodes :
 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 27 28 29
 ring nodes :
 1 2 3 4 5 6
 chain bonds :
 1-15 2-22 2-23 3-24 3-25 4-7 5-26 5-27 6-20 6-21 7-8 7-14 8-9 8-12
 8-13 9-10 9-11 15-28 28-29
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-28 28-29
 exact bonds :
 1-15 2-22 2-23 3-24 3-25 5-26 5-27 6-20 6-21 7-8 8-9 8-12 8-13
 isolated ring systems :
 containing 1 :

G1:H,Ak


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS
 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:01:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1580 TO ITERATE

100.0% PROCESSED 1580 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 29216 TO 33984

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:01:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 31904 TO ITERATE

100.0% PROCESSED 31904 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.02

L3 21 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 18:01:43 ON 31 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 30 Jan 2008 (20080130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 4 L3

=> d ibib abs hitstr tot


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:11297 CAPLUS
DOCUMENT NUMBER: 144:108213
TITLE: Preparation of piperidine and 8-azabicyclo[3.2.1]octane derivatives as modulators of chemokine receptor CCR5
INVENTOR(S): Faull, Alan; Tucker, Howard
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006001752	A1	20060105	WO 2005-SE953	20050620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005257708	A1	20060105	AU 2005-257708	20050620
CA 2570893	A1	20060105	CA 2005-2570893	20050620
EP 1761491	A1	20070314	EP 2005-754141	20050620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CN 101006057	A	20070725	CN 2005-80028432	20050620
US 2008021038	A1	20080124	US 2006-628808	20061207
IN 2007DN00246	A	20070803	IN 2007-DN246	20070109
PRIORITY APPLN. INFO.: SE 2004-1656 A 20040624				
WO 2005-SE953 W 20050620				

OTHER SOURCE(S): MARPAT 144:108213
GI

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Title compds. represented by the formula I [wherein A = absent or CH₂CH₂; R1 = alkyl, amide, (hetero)aryl, etc.; R2 = (un)substituted Ph or heteroaryl; R3 = H or alkyl; R4 = halo, hydroxy, cyano, etc.; R5 = aryl, alkoxyaryl, alkylaryl, etc.; and pharmaceutically acceptable salts thereof] were prepared as chemokine receptor (CCR5) modulators. For example, II was provided in a multi-step synthesis starting from 4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidine. I were tested activity as CCR5 modulators for inhibiting the binding of RANTES and MIP-1α, certain compds. have an IC₅₀ of less than 50 μM. Thus, I and their pharmaceutical compns. are useful for the treatment of CCR5-mediated diseases.

IT 872849-99-5P 872850-00-5P 872850-01-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine and 8-azabicyclo[3.2.1]octane derivs. as CCR5 modulators)
RN 872849-99-5 CAPLUS
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-fluoro-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 872850-00-5 CAPLUS
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-hydroxy-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 872850-01-6 CAPLUS
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 872850-25-4P, (1S)-3-[4-Methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]piperidin-1-yl]-1-phenylpropan-1-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidine and 8-azabicyclo[3.2.1]octane derivs. as

CCR5 modulators)
RN 872850-25-4 CAPLUS
CN 1-Piperidinepropanol, 4-methyl-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-α-phenyl-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:546479 CAPLUS
 DOCUMENT NUMBER: 141:106374
 TITLE: A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5
 INVENTOR(S): Cumming, John; Pauli, Alan; Fielding, Colin; Oldfield,
 PATENT ASSIGNEE(S): John; Tucker, Howard
 SOURCE: Astrazeneca AB, Swed.
 PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004056773	A1	20040708	WO 2003-SE2008	20031218	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG	CA 2508624	A1	20040708	CA 2003-2508624	20031218
AU 2003288856	A1	20040714	AU 2003-288856	20031218	
EP 1572650	A1	20050914	EP 2003-781235	20031218	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017459	A	20051116	BR 2003-17459	20031218	
CN 1732153	A	20060208	CN 2003-8010783	20031218	
JP 2006514107	T	20060427	JP 2005-502630	20031218	
IN 2005DN02442	A	20070406	IN 2005-DN2442	20050607	
MX 2005PA06381	A	20050829	MX 2005-PA6381	20050614	
US 2006189650	A1	20060824	US 2005-539859	20050617	
NO 2005003539	A	20050920	NO 2005-3539	20050719	
ZA 2005004616	A	20060329	ZA 2005-4616	20060116	
PRIORITY APPLN. INFO.:			SE 2002-3821	A 20021220	
			SE 2003-499	A 20030224	
			SE 2003-1425	A 20030515	
			WO 2003-SE2008	W 20031218	


OTHER SOURCE(S): MHPAT 141:106374
 GI

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB The invention relates to a preparation of novel piperidine derivs. of formula I
 [wherein: A is absent or (CH₂)₂; R₁ is alkyl, C(O)NH-alkyl, or CO₂-alkyl, etc.; R₂ is alkyl, Ph, heteroaryl, or cycloalkyl; R₃ is H or alkyl; R₄ is (hetero)aryl or (cyclo)alkyl; X is O or S(O)₀₋₂], useful as modulators of chemokine receptor CCR5. The invention compds. are claimed to be useful for the treatment of CCR5-mediated diseases such as autoimmune, inflammatory, or proliferative diseases. The invented compds. are also of value in inhibiting the entry of viruses (such as HIV) into target cells (no biol. data). The ability of the invention compds. to inhibit the binding of RANTES and MIP-1α was assessed (certain compds. of formula I have IC₅₀ < 50 μM). For instance, Pic50 (neg. log of the IC₅₀ result) for piperidine derivative II was determined as 6.91 (table XV).
 IT 718610-18-5P 718611-68-8P 718611-69-9P
 718611-70-2P 718611-71-3P 718611-72-4P
 718611-73-5P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of novel piperidine derivs. as modulators of chemokine receptor ccr5)
 RN 718610-18-5 CAPLUS
 CN Benzamide, 4-chloro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 718611-68-8 CAPLUS
 CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 718611-69-9 CAPLUS
 CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 718611-70-2 CAPLUS
 CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[[4-(fluorophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 718611-71-3 CAPLUS
 CN Butanamide, 4,4,4-trifluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-72-4 CAPLUS
 CN Cyclobutanecarboxamide, 3,3-difluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-73-5 CAPLUS
 CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 718610-15-2P 718610-19-6P 718610-23-2P
 718610-66-3P 718610-69-6P 718611-16-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Preparation of novel piperidine derivs. as modulators of chemokine
 receptor
 ccr5)

RN 718610-15-2 CAPLUS
 CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-[[4-(
 (methylsulfonyl)phenyl)sulfonyl]ethyl]- (CA INDEX NAME)




RN 718610-19-6 CAPLUS
 CN 1-Piperidinepropanamine, 4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-
 α-phenyl-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.




RN 718610-23-2 CAPLUS
 CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-[[4-(
 fluorophenyl)sulfonyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT




RN 718610-66-3 CAPLUS
 CN 1-Piperidinepropanol, 4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-
 α-phenyl- (CA INDEX NAME)



RN 718610-69-6 CAPLUS
 CN 1-Piperidinepropanol, 4-[2-[[4-(fluorophenyl)sulfonyl]ethyl]-α-phenyl-
 , (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 718611-16-6 CAPLUS
 CN Carbamic acid,
 [(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-
 piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 1974:505305 CAPLUS
 DOCUMENT NUMBER: 81:105305
 ORIGINAL REFERENCE NO.: 81:16651a,16654a
 TITLE: 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-piperidine-4-
 carboxylic acid derivatives
 INVENTOR(S): Briggs, Frederick B.
 PATENT ASSIGNER(S): G.D. Searle and Co.
 SOURCE: Brit., 11 pp. Division of Brit. 1,356,117.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1356118	A	19740612	GB 1971-57390	19701216
PRIORITY APPLN. INFO.:			GB 1971-57390	A 19701216

G1 For diagram(s), see printed CA Issue.
 AB Seventeen title derivs. I.HCl (R = heteroaryloxy, substituted phenoxy,
 amino, hydrazino, alkoxy, and alkylthio) diarrhea inhibitors which also
 counteract the withdrawal symptoms associated with chronic psychotropic
 drug

intoxication (no data), were prepared from the title acid I (R = OH). I
 possess analgesic, antiprotzoal, antibacterial, antifungal, and
 anthelmintic activity (no data).

IT 37983-42-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 37983-42-9 CAPLUS
 CN 4-Piperidinecarbothioic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-,
 S-(2,4-dichlorophenyl) ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1972:539819 CAPLUS
DOCUMENT NUMBER: 77:139819
ORIGINAL REFERENCE NO.: 77:22985a, 22988a
TITLE: 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid derivatives
INVENTOR(S): Kreider, Bunice M. S.
PATENT ASSIGNEE(S): G.D. Searle and Co.
SOURCE: Ger. Offen., 35 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2161827	A	19720706	DE 1971-2161827	19711213
GB 1356117	A	19740612	GB 1970-59686	19701216
CA 947296	A1	19740514	CA 1971-129748	19711209
BE 776644	A1	19720613	BE 1971-111627	19711213
BE 776645	A1	19720613	BE 1971-111628	19711213
NL 7117061	A	19720620	NL 1971-17061	19711213
NL 7117062	A	19720620	NL 1971-17062	19711213
FR 2118060	A5	19720728	FR 1971-44705	19711213
FR 2118060	B1	19751031		
FR 2118061	A5	19720728	FR 1971-44706	19711213
FR 2118061	B1	19751010		
AU 7136783	A	19730614	AU 1971-36783	19711213
AU 7136784	A	19730614	AU 1971-36784	19711213
ES 397911	A1	19750416	ES 1971-397911	19711213
ES 397912	A1	19750416	ES 1971-397912	19711213
DK 130966	B	19750512	DK 1971-6076	19711213
CH 572037	A5	19760130	CH 1971-18174	19711213
CH 572920	A5	19760227	CH 1971-18173	19711213
CH 572922	A5	19760227	CH 1974-16946	19711213
CH 572923	A5	19760227	CH 1974-16947	19711213
DK 136037	B	19770801	DK 1971-6075	19711213
JP 55042996	B	19801104	JP 1971-100937	19711213
ZA 7108379	A	19730228	ZA 1971-8379	19711214
ZA 7108380	A	19730228	ZA 1971-8380	19711214
SE 370542	B	19741021	SE 1971-15978	19711214
SE 370543	B	19741021	SE 1971-15979	19711214
US 3843646	A	19741022	US 1971-208445	19711215
US 3847923	A	19741112	US 1971-208442	19711215
ES 400478	A1	19750101	ES 1972-400478	19720306
ES 400479	A1	19750116	ES 1972-400479	19720306
US 3959275	A	19760525	US 1974-473750	19740528
JP 55120584	A	19800917	JP 1980-7378	19800124
JP 56004556	B	19810130		
JP 55127388	A	19801002	JP 1980-7379	19800124
JP 56006429	B	19810210		
PRIORITY APPLN. INFO.:			GB 1970-59686	A 19701216
			US 1971-208442	A3 19711215

OTHER SOURCE(S): MARPAT 77:139819
GI For diagram(s), see printed CA Issue.
AB Eighteen title compds. (I, e.g. R = 2-pyridyloxy, 2-pyridylmethoxy, 2,4,5-Cl3C6H2O (II), 3,4-Me(Me)C6H3, 2,4-Cl2C6H3, PhCH2S, phthalimidomethoxy, Me2NNH, 4-MeOC6H4NH and (or) their mono- or


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
dihydrochlorides, useful as antidiarrheal drugs, were prepd. by reaction of I (R = OH or Cl) with RH. Thus, 2,4,5-Cl3C6H2OH and dicyclohexylcarbodiimide were added to I (R = OH) in DMF and the mixt.

was stirred 24 hr to give II.
IT 37983-42-9P 37983-44-1P
RL: SPW (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37983-42-9 CAPLUS
CN 4-Piperidinecarbothioic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, S-(2,4-dichlorophenyl) ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 37983-44-1 CAPLUS
CN 4-Piperidinecarbothioic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, S-2-furanyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d his

(FILE 'HOME' ENTERED AT 18:00:17 ON 31 JAN 2008)

FILE 'REGISTRY' ENTERED AT 18:00:27 ON 31 JAN 2008

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 21 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:01:43 ON 31 JAN 2008

L4 4 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.76

201.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.20

-3.20

STN INTERNATIONAL LOGOFF AT 18:03:06 ON 31 JAN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:11:36 ON 31 JAN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:11:43 ON 31 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1
DICTIONARY FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10564509a.str



chain nodes :

7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 27 30 31 32 33

ring nodes :

1 2 3 4 5 6 28 29

chain bonds :

1-15 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13 9-10
9-11 15-26 26-27 28-30 28-31 29-32 29-33

ring bonds :

1-2 1-6 2-3 3-4 3-29 4-5 5-6 5-28 28-29

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-26 26-27

exact bonds :

1-15 2-22 2-23 3-24 3-29 5-25 5-28 6-20 6-21 7-8 8-9 8-12 8-13 28-29
28-30 28-31 29-32 29-33

isolated ring systems :

containing 1 :

G1:H,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 28:Atom 29:Atom 30:CLASS
31:CLASS 32:CLASS 33:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:12:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 119 TO 641

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:12:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 411 TO ITERATE

100.0% PROCESSED 411 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

STN INTERNATIONAL LOGOFF AT 18:12:17 ON 31 JAN 2008